{"id":"W2153921055","doi":"10.1158/1078-0432.ccr-08-0529","title":"Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Rituximab; Medicine; Chemoimmunotherapy; Radioimmunotherapy; Follicular lymphoma; Ibritumomab tiuxetan; CHOP; Nuclear medicine; Vincristine; Lymphoma; Internal medicine; Gastroenterology; Cyclophosphamide; Chemotherapy; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001712347,0.0002865263,0.00129601,0.0002041079,0.000215555,0.00002136331,0.0002144424,0.0003093914,0.000181998],"category_scores_gemma":[0.0007445407,0.0002266628,0.0003420407,0.0006925812,0.0008192689,0.0001035973,0.0001890352,0.0003563609,0.00001618566],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004058466,"about_ca_system_score_gemma":0.001303248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001734385,"about_ca_topic_score_gemma":0.0002728051,"domain_scores_codex":[0.9955082,0.0005548674,0.001203444,0.0008565253,0.001095357,0.000781609],"domain_scores_gemma":[0.9975185,0.0007256342,0.000121906,0.0007052921,0.000330308,0.0005983861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1797486,0.2026321,0.2042956,0.000272902,0.001280228,0.005045186,0.0006289476,7.674143e-7,0.001506785,0.00009751106,0.06143166,0.3430597],"study_design_scores_gemma":[0.8445476,0.03599809,0.09787589,0.0006310008,0.0004539073,0.000111823,0.00009802337,0.0002372915,0.00572828,0.00009047818,0.01383242,0.0003952092],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831917,0.01163046,0.000001011372,0.001724861,0.0001654384,0.002477525,0.00007855054,0.00003884608,0.0006916277],"genre_scores_gemma":[0.9850834,0.01285173,0.00006472164,0.0001286129,0.0002943367,0.000662658,0.00006771962,0.00004407488,0.0008027293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.664799,"threshold_uncertainty_score":0.9243041,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1457220537021659,"score_gpt":0.4981432744785355,"score_spread":0.3524212207763696,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}